Sacituzumab manufacturers
- Sacituzumab
-
- $163.00
-
2026-06-10
- CAS:1796566-95-4
- Purity: 95.00%
- Supply Ability: 10g
|
| | Sacituzumab Basic information |
| Product Name: | Sacituzumab | | Synonyms: | Sacituzumab;Research Grade Sacituzumab(DHC43301);Sacituzumab (anti-TROP2);Sacituzumab|||Sacituzumab (anti-Trop-2);Research Grade Sacituzumab;(2R)-2-amino-3-[1-[[4-[[1-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[2-[2-[[(2S)-6-amino-1-[4-[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxycarbonyloxymethyl]anilino]-1-oxohexan-2-yl]amino]-2-oxoethoxy]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]methylcarbamoyl]cyclohexyl]methyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid | | CAS: | 1796566-95-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Sacituzumab Structure]() |
| | Sacituzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Sacituzumab Usage And Synthesis |
| Uses | Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer[1][2][3][4]. | | in vivo | Sacituzumab (50 mg/kg, i.v., every 5 days for four times) exhibits a weak antitumor effect without significant weight loss in MDA-MB-468 xenograft mouse model[1]. | Animal Model: | MDA-MB-468 xenograft model of 6-week-old female BALB/c nude mice[1] | | Dosage: | 50 mg/kg | | Administration: | i.v., intervals of 5 days and repeated a total of four times | | Result: | Decreased the tumor inhibition rate to 29.1% at 50 mg/kg in MDA-MB-468 xenograft model. |
| | References | [1] Zhou DD, et al. Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2[J]. Int J Biol Macromol. 2023 Dec 31;253(Pt 6):127105. DOI:10.1016/j.ijbiomac.2023.127105
[2] Sun M, et al. Structural insights into the cis and trans assembly of human trophoblast cell surface antigen 2[J]. iScience. 2021 Sep 30;24(10):103190. DOI:10.1016/j.isci.2021.103190
[3] Shih LB, et al. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer[J]. Cancer Res. 1995 Dec 1;55(23 Suppl):5857s-5863s. PMID:7493360
[4] Bardia A, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021 Sep;32(9):1148-1156. DOI:10.1016/j.annonc.2021.06.002 |
| | Sacituzumab Preparation Products And Raw materials |
|